Panacea Biotec share news, announcements and annual reports
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Panacea Biotec Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on BSE, Apr 1996 on NSE
Last close ₹327.75up ₹14.50 (4.63%)BSE ₹326.65
Share price at the NSE close on 2 Nov 2026. Previous close ₹313.25.
2 Nov: open ₹315.50, high ₹329.75, low ₹314.95
52-week range of traded prices to 2 Nov 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,007 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 48,28047.7% delivered
Panacea Biotec share news and announcements
875 announcements, routine notices left out, newest first. Page 12 of 18.
Sep 2017
14 Sep · Legal
Exchange has sought clarification from Panacea Biotec Limited with respect to announcement dated 13-Sep-2017, regarding " Outcome of Board Meeting held on September 13, 2017.". On basis of above the Company is required to clarify following: 1. Brief details of the division to be demerged;2. Turnover of the demerged division and as percentage to the total turnover of the listed entity in the immediately preceding financial year / based on financials of the last financial year;3. Rationale for demerger;4. Brief details of change in shareholding pattern (if any)of all entities;5. In case of cash consideration amount or otherwise share exchange ratio;6. Whether listing would be sought for the resulting entity;The response of the Company is awaited.13 Sep · Board meeting
13 Sep · Results
Aug 2017
31 Aug · Updates
Jul 2017
Jun 2017
May 2017
30 May · Results
Apr 2017
Mar 2017
1 Mar · News Verification
Exchange has sought clarification from Panacea Biotec Limited with respect to recent news item captioned "Narayana Hrudayalaya in advanced talks to buy Panacea Biotec's Gurgaon hospital".. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Feb 2017
14 Feb · Results
Jan 2017
Dec 2016
Nov 2016
11 Nov · Results
Oct 2016
Sep 2016
30 Sep · Regulation 44(3) of SEBI (LODR), Reg., 2015
Aug 2016
Jul 2016
Jun 2016
May 2016
Apr 2016